Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing.

Sun D, Wen H, Externbrink A, Gao Z, Keire D, Krauss G, Jiang W.

CNS Drugs. 2016 May;30(5):455-60. doi: 10.1007/s40263-016-0332-9.

PMID:
27048352
2.

Assessing bioequivalence of generic modified-release antiepileptic drugs.

Johnson EL, Chang YT, Davit B, Gidal BE, Krauss GL.

Neurology. 2016 Apr 26;86(17):1597-604. doi: 10.1212/WNL.0000000000002607. Epub 2016 Mar 25.

PMID:
27016518
3.

Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.

Krauss G, Faught E, Foroozan R, Pellock JM, Sergott RC, Shields WD, Ziemann A, Dribinsky Y, Lee D, Torri S, Othman F, Isojarvi J.

Epilepsy Behav. 2016 Mar;56:15-9. doi: 10.1016/j.yebeh.2015.12.004. Epub 2016 Jan 22.

PMID:
26807550
4.

Epilepsy care in the southern Caribbean.

Krauss G, Sandy S, Corbin DO, Bird-Compton J, Jack F, Nelson B, Jalonen TO, Ali A, Fortuné T, Clarke D, Okolie J, Cervenka MC.

Epilepsy Behav. 2015 Oct;51:267-72. doi: 10.1016/j.yebeh.2015.07.011. Epub 2015 Aug 24.

PMID:
26312988
5.

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.

French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, Trinka E, O'Brien TJ, Laurenza A, Patten A, Bibbiani F.

Neurology. 2015 Sep 15;85(11):950-7.

6.

Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance.

Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M.

Neuroimage Clin. 2015 Feb 21;7:688-98. doi: 10.1016/j.nicl.2015.02.009. eCollection 2015.

7.

Should "historic control" epilepsy monotherapy trials be "history"?

Krauss GL.

Epilepsy Curr. 2015 Jan-Feb;15(1):8-9. doi: 10.5698/1535-7597-15.1.8. No abstract available.

8.

Epilepsy is not resolved.

Krauss G.

Epilepsy Curr. 2014 Nov-Dec;14(6):339-40. doi: 10.5698/1535-7597-14.6.339. No abstract available.

9.

Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years.

Rosenfeld W, Fountain NB, Kaubrys G, Ben-Menachem E, McShea C, Isojarvi J, Doty P; SP615 Study Investigators.

Epilepsy Behav. 2014 Dec;41:164-70. doi: 10.1016/j.yebeh.2014.09.074. Epub 2014 Oct 27.

PMID:
25461210
10.

Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy.

Sperling MR, Haas KF, Krauss G, Seif Eddeine H, Henney HR 3rd, Rabinowicz AL, Bream G, Squillacote D, Carrazana EJ.

Epilepsia. 2014 Oct;55(10):1544-50. doi: 10.1111/epi.12755. Epub 2014 Aug 25.

11.

Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity.

Yoon KJ, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z, Makri G, Nauen D, Shin JH, Park Y, Chung R, Pekle E, Zhang C, Towe M, Hussaini SM, Lee Y, Rujescu D, St Clair D, Kleinman JE, Hyde TM, Krauss G, Christian KM, Rapoport JL, Weinberger DR, Song H, Ming GL.

Cell Stem Cell. 2014 Jul 3;15(1):79-91. doi: 10.1016/j.stem.2014.05.003. Erratum in: Cell Stem Cell. 2015 Mar 5;16(3):339.

12.

"Idiopathic" and "genetic" generalized epilepsies intersect.

Krauss G, Barañano K.

Epilepsy Curr. 2014 Mar;14(2):81-3. doi: 10.5698/1535-7597-14.2.81. No abstract available.

13.

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang X, Bagul M, Gee M, Zhu J, Squillacote D.

Epilepsia. 2014 Jul;55(7):1058-68. doi: 10.1111/epi.12643. Epub 2014 May 27.

14.

Epilepsy: responsive neurostimulation-modulating the epileptic brain.

Ben-Menachem E, Krauss GL.

Nat Rev Neurol. 2014 May;10(5):247-8. doi: 10.1038/nrneurol.2014.69. Epub 2014 Apr 22. No abstract available.

PMID:
24752127
15.

Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.

Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Laurenza A, Yang H, Zhu J, Squillacote D.

Epilepsia. 2014 Mar;55(3):423-31. doi: 10.1111/epi.12527. Epub 2014 Mar 7.

16.

Degradation of benzodiazepines after 120 days of EMS deployment.

McMullan JT, Jones E, Barnhart B, Denninghoff K, Spaite D, Zaleski E, Silbergleit R; Neurological Emergencies Treatment Trials investigators.

Prehosp Emerg Care. 2014 Jul-Sep;18(3):368-74. doi: 10.3109/10903127.2013.869642. Epub 2014 Feb 18.

17.

Perampanel: a selective AMPA antagonist for treating seizures.

Krauss GL.

Epilepsy Curr. 2013 Nov;13(6):269-72. doi: 10.5698/1535-7597-13.6.269.

18.

Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol.

French JA, Krauss GL, Kasteleijn D, DiVentura BD, Bagiella E.

Neurotherapeutics. 2014 Apr;11(2):412-8. doi: 10.1007/s13311-013-0243-0.

19.

New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists.

Bell SG, Matsumoto M, Shaw SJ, Brandt J, Krauss GL.

Epilepsy Behav. 2013 Oct;29(1):36-40. doi: 10.1016/j.yebeh.2013.06.008. Epub 2013 Aug 7.

20.

Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials.

Hesdorffer DC, French JA, Posner K, DiVentura B, Pollard JR, Sperling MR, Harden CL, Krauss GL, Kanner AM.

Epilepsia. 2013 May;54(5):879-87. doi: 10.1111/epi.12128. Epub 2013 Feb 28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk